Wei Bai
Impact in
- Clinical Biochemistry top 2%
- Advanced Glycation End Products research
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- RNA Research and Splicing 4
- Circular RNAs in diseases 4
- RNA modifications and cancer 4
-
- Cancer-related molecular mechanisms research 8
- MicroRNA in disease regulation 3
- Co-authors
- Rama Natarajan (8 shared papers)Jerry L. Nadler (6 shared papers)Mausumee Guha (1 shared paper)Bobby V. Khan (1 shared paper)Russell M. Medford (1 shared paper)Noe Gonzales (3 shared papers)David S. Levin (1 shared paper)Alan E. Tomkinson (1 shared paper)
- Journals
- Hypertension (2 papers)Journal of Cachexia Sarcopenia and Muscle (2 papers)Clinical & Translational Oncology (1 paper)Schizophrenia Bulletin (1 paper)Journal of Cellular Biochemistry (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Wei Bai
42 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 132
- Clinical Biochemistry 168
- Cancer Research 364
- Molecular Medicine 91
- Molecular Biology 1.1k
- Biochemistry 102
Countries citing papers authored by Wei Bai
This map shows the geographic impact of Wei Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Bai more than expected).
Fields of papers citing papers by Wei Bai
This network shows the impact of papers produced by Wei Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Bai. The network helps show where Wei Bai may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Bai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 267 | |
| 2 | 1999 | 261 | |
| 3 | 1997 | 196 | |
| 4 | 2010 | 179 | |
| 5 | 2005 | 149 | |
| 6 | 1997 | 110 | |
| 7 | 1999 | 84 | |
| 8 | 2013 | 83 | |
| 9 | 1997 | 56 | |
| 10 | 1996 | 53 | |
| 11 | 1997 | 52 | |
| 12 | 2018 | 51 | |
| 13 | 1997 | 49 | |
| 14 | 2020 | 47 | |
| 15 | 2018 | 43 | |
| 16 | 2016 | 38 | |
| 17 | 2015 | 37 | |
| 18 | 2021 | 34 | |
| 19 | 2019 | 30 | |
| 20 | 2022 | 25 |
About Wei Bai
Wei Bai is a scholar working on Molecular Biology, Cancer Research, Physiology, Immunology and Epidemiology, having authored 45 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (8 papers), Advanced Glycation End Products research (5 papers), Eicosanoids and Hypertension Pharmacology (5 papers), RNA Research and Splicing (4 papers), Circular RNAs in diseases (4 papers), RNA modifications and cancer (4 papers), MicroRNA in disease regulation (3 papers) and Inflammatory mediators and NSAID effects (3 papers). The work is most often cited by research in Clinical Biochemistry (168 citations), Cancer Research (364 citations), Molecular Medicine (91 citations), Molecular Biology (1.1k citations) and Biochemistry (102 citations). Wei Bai has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Rama Natarajan, Jerry L. Nadler, Mausumee Guha, Bobby V. Khan, Russell M. Medford, Noe Gonzales, David S. Levin, Alan E. Tomkinson, Linda Lanting and Nina Y. Yao. Their work appears in journals such as Hypertension, Journal of Cachexia Sarcopenia and Muscle, Clinical & Translational Oncology, Schizophrenia Bulletin and Journal of Cellular Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.